AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9409050
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg tablets, two tablets administered pre-operatively)
Trial: 9409050
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two matching placebo tablets administered pre-operatively)
Trial: 8287650
Drug: 5-hydroxy-L-tryptophan
RxNorm normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxy-L-tryptophan
Trial: 8287650
Drug: gamma-L-glutamyl-5-hydroxy-L-tryptophan
RxNorm normalized name: L-glutamyl-L-tryptophan
DrugBank: Oglufanide (DB05779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma-L-glutamyl-5-hydroxy-L-tryptophan
Trial: 3518771
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release nifedipine 40 mg at 1 and 12 h
Trial: 3518771
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg at 0 h
Trial: 20519807
Drug: Miglitol administered
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol administered at 30 min after the start of a meal (50 mg)
Trial: 12907008
Drug: MnCC control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MnCC control vaccine
Trial: 8737229
Drug: r‐HuEpo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEpo (200 U, subcutaneously administered, three times weekly for 4 weeks)
Trial: 7055169
Drug: Laminaria treatment
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria treatment (n = 45)
Trial: 30783732
Drug: Mometasone (inhaled)
RxNorm normalized name: mometasone Inhalant Product
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone (inhaled)
Trial: 17580534
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once daily (n = 18)
Trial: 17580534
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin twice daily (n = 15)
Trial: 17580534
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin once daily at bedtime with more intensive self-monitoring (n = 15)
Trial: 9672774
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg o.d. for 10 days)
Trial: 30783776
Drug: Collagen peptides
RxNorm normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen peptides (CP) 20 g day−1
Trial: 26867337
Drug: Thymosin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin therapy (1.6 mg subcutaneous injection, qd X 7 d)
Trial: 26867337
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy (ICU conventional treatment)
Trial: 22763798
Drug: L-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine supplementation (7 g/day for 1 week)
Trial: 21971663
Drug: L‐Ala‐Gln 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐Ala‐Gln 20% plus saline 750 ml (Group L‐Ala‐Gln, n=11)
Trial: 21971663
Drug: Saline 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 1000 ml (Group Saline, n=11)
Trial: 16709595
Drug: No diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No diuretic use
Trial: 15508179
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with birch pollen extract
Trial: 11430776
Drug: Energy restriction
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy restriction (‐2929 kJ/d) and drug therapy (or placebo)
Trial: 9153530
Drug: Control (patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (patients prior to treatment)
Trial: 7974898
Drug: Colony-stimulating factor
RxNorm normalized name: Colony-stimulating factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colony-stimulating factor support for chemotherapy
Trial: 7974898
Drug: Adjunctive surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive surgical therapy
Trial: 2455188
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine (TC)
Trial: 2455188
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol (OP)
Trial: 25720615
Drug: Lactobacillus brevis
RxNorm normalized name: Lactobacillus brevis
DrugBank: Lactobacillus brevis (DB18532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus brevis CD2 lozenges, three times daily for 14 days
Trial: 25720615
Drug: Placebo, three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, three times daily for 14 days
Trial: 10811265
Drug: Calcium pentosan
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium pentosan polysulphate (CaPPS) 10 mg/kg orally, once weekly for four weeks, repeated every 12 weeks.
Trial: 8781669
Drug: L-ASA (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ASA (90 mg/ml)
Trial: 8781669
Drug: Placebo (glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glycine solution 30 mg/ml)
Trial: 1616392
Drug: Mefloquine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 15 mg kg-1 (M15)
Trial: 1616392
Drug: Mefloquine 25
RxNorm normalized name: mefloquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 25 mg kg-1 (M25)
Trial: 1616392
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) treatment failures treated with Mefloquine 25 mg kg-1
Trial: 25304187
Drug: Antenatal distribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal distribution of misoprostol (for self-administration after home birth or when oxytocin is not available)
Trial: 8551485
Drug: Verapamil 120-240
RxNorm normalized name: verapamil hydrochloride 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120-240 mg once daily for 8 weeks
Trial: 7008821
Drug: Azatadine maleate
RxNorm normalized name: Azatadine Maleate
DrugBank: Azatadine (DB00719)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azatadine maleate (4 mg/day for 1 week)
Trial: 22002564
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy concurrent with letrozole 2.5 mg (study arm, n = 50)
Trial: 22002564
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy alone (control arm, n = 51)
Trial: 19307972
Drug: Propofol target-controlled
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target-controlled infusion based on a weight adjustment formula (group adjusted)
Trial: 19307972
Drug: Propofol target-controlled
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target-controlled infusion without adjustment (group total body weight - TBW)
Trial: 14993502
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (1.5-2.0 mg/kg/day for 12 months) and steroids (methylprednisolone pulses 3 x 1 g, i.v. at months 1, 3 and 5, and oral prednisone 0.5 mg/kg/48 h for 6 months)
Trial: 14993502
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (not specified treatment)
Trial: 2239778
Drug: Vegetable-protein mixed
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable-protein mixed diet at 96, 128, 160, and 192 mg N.kg body wt‐1.d‐1 for 10 days
Trial: 2239778
Drug: Milk-egg protein
RxNorm normalized name: milk protein concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-egg protein diet at 160 mg N.kg‐1.d‐1 for 10 days
Trial: 348260
Drug: Metoprolol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 300 mg in a single daily dose
Trial: 348260
Drug: Metoprolol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 300 mg/day in three doses
Trial: 27941119
Drug: Oral amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin, 2 times daily for 7 days
Trial: 27941119
Drug: Placebo, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 times daily for 7 days
Trial: 24828121
Drug: Drinking 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking 400 mL water
Trial: 24828121
Drug: Drinking 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking 400 mL water and eating a 6-inch Subway sandwich
Trial: 24828121
Drug: Drinking 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking 400 mL water and composing 3 text messages
Trial: 23421352
Drug: 40 IU
RxNorm normalized name: Oxytocin 40 IU/1 ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU intranasal oxytocin for 10 consecutive days
Trial: 19169446
Drug: 0.2% solution
RxNorm normalized name: Naropin 0.2% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% solution of CHX
Trial: 19169446
Drug: 0.12% solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% solution of CHX
Trial: 19169446
Drug: 0.2% gel
RxNorm normalized name: SIROLIMUS 0.2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% gel
Trial: 19169446
Drug: 0.2% spray
RxNorm normalized name: HYALURONATE NA 0.2% SPRAY,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% spray
Trial: 19169446
Drug: 0.12% spray
RxNorm normalized name: BENZETHONIUM CL 0.12% SPRAY,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% spray
Trial: 19169446
Drug: swab with
RxNorm normalized name: Suction Swab with Corinz Oral Rinse KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: swab with 0.2% solution
Trial: 15781531
Drug: Heparinized flush
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized flush solution (group H, n = 100)
Trial: 15781531
Drug: Nonheparinized flush
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonheparinized flush solution (group S, n = 100)
Trial: 15781531
Drug: Heparinized flush
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized flush solution (group H)
Trial: 15781531
Drug: Nonheparinized flush
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonheparinized flush solution (group S)
Trial: 8742916
Drug: Vasopressin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin (0.3 U/min) plus nasal oxygen (4 L/min)
Trial: 1655647
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (50 ng x kg-1 x min-1)
Trial: 25192333
Drug: NP001 (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP001 (0.2, 0.8, 1.6, and 3.2 mg/kg, single i.v. dose)
Trial: 20848453
Drug: NI-0401 (0.05-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NI-0401 (0.05-10 mg daily for 5 days)
Trial: 20848453
Drug: NI-0401 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NI-0401 (1 mg)
Trial: 17428106
Drug: Montelukast with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast with antihistamines (loratadine or cetirizine)
Trial: 9857783
Drug: Medication noncompliance
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication noncompliance and substance abuse
Trial: 9857783
Drug: Problems with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problems with both alcohol and illicit drug abuse
Trial: 9857783
Drug: Improving medication
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Improving medication adherence in the context of integrated mental health and substance abuse treatment
Trial: 7542829
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean daily dose 8 mg)
Trial: 7542829
Drug: Zuclopenthixol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuclopenthixol (mean daily dose 38 mg)
Trial: 31564184
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiotherapy with 20 Gy in five fractions followed by four cycles of chemotherapy (FOLFOX regimen)
Trial: 29723460
Drug: Qilan Capsules
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qilan Capsules + androgen‐deprivation therapy
Trial: 29723460
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + androgen‐deprivation therapy
Trial: 22472905
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PT and RM
Trial: 26490089
Drug: benidipine-β-blocker
RxNorm normalized name: barnidipine
DrugBank: Barnidipine (DB09227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benidipine-β-blocker
Trial: 21610513
Drug: benidipine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benidipine and thiazide diuretic
Trial: 17972364
Drug: 5 STIs
RxNorm normalized name: Stissera Curcuma Root
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 STIs of 1, 1, 2, 2, and 3 months' duration, each followed by 3 months of therapy
Trial: 17972364
Drug: Unboosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unboosted protease inhibitor (PI)-based HAART
Trial: 17972364
Drug: Non-nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleoside reverse transcriptase inhibitor-based HAART
Trial: 15143085
Drug: Low-dose HER‐2/neu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose HER‐2/neu ICD protein vaccine (25 microg)
Trial: 15143085
Drug: Intermediate-dose HER‐2/neu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose HER‐2/neu ICD protein vaccine (150 microg)
Trial: 15143085
Drug: High-dose HER‐2/neu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose HER‐2/neu ICD protein vaccine (900 microg)
Trial: 15143085
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of HER‐2/neu ICD protein vaccine
Trial: 11801946
Drug: TCRF turbinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCRF turbinate treatment (mean energy 415 +/- 37 J/turbinate; n = 17)
Trial: 9494309
Drug: Perceived control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived control over pain and taking pain medication
Trial: 2461906
Drug: 10% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydroxyethyl starch (HES) solution
Trial: 2461906
Drug: 10% dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextran solution
Trial: 30033775
Drug: CARE Healthy
RxNorm normalized name: CHLOROXYLENOL 0.005 mg in 1 mL TOPICAL LIQUID [PURELL Healthcare HEALTHY SP 0.5pct PCMX Antimicrobial Foam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CARE Healthy Lifestyles intervention (includes educational workshop, informational magazine, goal setting, weekly self-monitoring, tailored feedback, prompts, team-based goals, coaching for directors)
Trial: 29625849
Drug: AbobotulinumtoxinA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA (both doses)
Trial: 16688464
Drug: Concurrent pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent pain in axial, upper limb, and lower limb areas
Trial: 11012500
Drug: Isobaric 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric 2% lidocaine 4 ml intrathecally
Trial: 11012500
Drug: Isobaric 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric 2% prilocaine 4 ml intrathecally
Trial: 26832658
Drug: IAI 2
RxNorm normalized name: Intravitreal aflibercept injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAI 2 mg every 8 weeks after 5 monthly doses (2q8)
Trial: 15539894
Drug: Calcipotriol/betamethasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol/betamethasone dipropionate followed by calcipotriol 50 microg/g once daily
Trial: 15539894
Drug: Tacalcitol 4
RxNorm normalized name: Tacalcitol 4 microgram/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacalcitol 4 microg/g once daily
Trial: 11157302
Drug: Glucagon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (1 mg IV)
Trial: 11157302
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mg IV)
Trial: 11157302
Drug: Open-label glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open-label glucagon (1 mg IV)
Trial: 9691869
Drug: DCLHb 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCLHb 400 mg kg‐1 i.v.
Trial: 26709158
Drug: Tobramycin powder
RxNorm normalized name: tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin powder for inhalation (TIP)
Trial: 22884560
Drug: Ranolazine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (500 to 1,000 mg orally twice daily)
Trial: 21047592
Drug: Active monitoring,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active monitoring, radiotherapy, and radical prostatectomy treatments
Trial: 11980329
Drug: Vancomycin 2
RxNorm normalized name: vancomycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 2 g per day (Group 1, n = 10)
Trial: 11980329
Drug: Vancomycin with
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin with cefpirome 2 g x 2 (Group 2, n = 10)
Trial: 10077374
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg) once daily
Trial: 10077374
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg) once daily
Trial: 7562574
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous cocaine doses (0, 8, 16, 32 or 48 mg/70 kg) administered 1 hr after daily methadone
Trial: 7562574
Drug: Repeated intravenous
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated intravenous cocaine doses (0, 8 or 32 mg/70 kg) administered 4 times per session at 14‐min intervals
Trial: 7562574
Drug: Higher methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher methadone doses (> 60 mg)
Trial: 7562574
Drug: Cocaine administration
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine administration in methadone-maintained individuals
Trial: 7396155
Drug: Alcohol 0.5
RxNorm normalized name: isopropyl alcohol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol 0.5 mg/kg
Trial: 29078780
Drug: Apple polyphenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple polyphenol extract (100 mg epicatechin daily for 4 weeks)
Trial: 25749867
Drug: NNC0109-0012 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC0109-0012 administered subcutaneously at various dose levels (0.01-3 mg/kg) as single dose, once weekly, or multiple doses every second week for up to 12 doses.
Trial: 24732962
Drug: Internet-based writing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based writing therapy with therapeutic interaction, 14 sessions
Trial: 27247843
Drug: Medication (placebo)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (placebo)
Trial: 28103159
Drug: Medication (methylphenidate)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (methylphenidate) without sports training
Trial: 25891307
Drug: Individual reminiscence
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual reminiscence therapy (1 hour/week for 4 weeks)
Trial: 24063204
Drug: Tongguan Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongguan Capsule (TC)
Trial: 14764772
Drug: Cabergoline treatment
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline treatment for 6 months
Trial: 8620275
Drug: Meropenem (MP)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MP) 1,000 mg every eight hours
Trial: 8620275
Drug: Tobramycin 5
RxNorm normalized name: tobramycin 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 5 mg/kg/day and Clindamycin 900 mg every eight hours (T/C)
Trial: 18200773
Drug: Controlled-release nifedipine
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release nifedipine added once daily to ARB